Search

everythinglearnresearchcommunity

for

Search:↓

Combination therapies might work better for some vitiligo patients, but results vary.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

Tofacitinib is an effective and safe treatment for alopecia areata.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

Tofacitinib may help treat severe hair loss, but more research is needed.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Tofacitinib is a promising treatment for children with rheumatic diseases.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.